[Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?].
The clinical-biochemical syndrome of cholestasis is characterized by an alteration in bile constituents. As a consequence, the concentrations of bilirubin, bile acids, phospholipids and cholesterol are elevated. The main clinical symptoms of cholestasis are icterus and pruritus, and in severe cases xanthelasma and xanthoma. Primary intrahepatic cholestasis, caused by impaired bile secretion in the liver, should be separated from the extrahepatic secondary cholestasis which is a consequence of a biliary obstruction. This paper evaluates the therapy of liver diseases which developed as consequence of a primary disturbance in bile secretion.
Pausch
J
J
Medizinische Klinik I, Klinikum Kassel GmbH, Kassel. med-klinik1@klinikum-kassel
Gatzen
M
M
D000328:Adult; D000367:Age Factors; D001647:Bile Acids and Salts / Q000378:metabolism; D001650:Bile Duct Neoplasms / Q000209:etiology / Q000517:prevention & control; D018281:Cholangiocarcinoma / Q000209:etiology / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000209:etiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000209:etiology; D008134:Long-Term Care; D008875:Middle Aged; D011247:Pregnancy; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*
D001647:Bile Acids and Salts; D014580:Ursodeoxycholic Acid